Disposition of Comments
Project ID: GENC0609
The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment (TA)
Program supports and is committed to the transparency of its review process. Therefore,
invited peer review comments and public review comments are publicly posted on the TA
Program Web site at http://www.ahrq.gov/clinic/techix.htm
within 3 months after the associated final report is posted.
This document presents the peer review comments and public review comments
sent in response to the draft report, Update of Genetic Tests for Non-Cancer
and Cancer Diseases and Conditions, which was made available for comment on the
AHRQ Web site
Select for the print
version (PDF file, 176 KB). Plugin Software Help.
Tables
Select for Table
1.
Invited Peer Reviewer Comments
Select for Table
2. Public Reviewer Comments
Current as of October 2010
Internet Citation:
Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Disposition of Comments. June 2010. Rockville, MD: Agency for Healthcare Research
and Quality. http://www.ahrq.gov/clinic/ta/comments/pharmgentests/